European consensus table on the use of botulinum toxin type a in adult spasticity

Journal of Rehabilitation Medicine

Volumn 41, Issue 1, 2009, Pages 13-25

  Wissel, Jörg ^a   Ward, Anthony B ^b   Erztgaard, Per ^c   Bensmail, Djamel ^d   Hecht, Martin J ^e   Lejeune, Thierry M ^f   Schnider, Peter ^g   Altavista, Maria C ^h   Cavazza, Stefano ⁱ   Deltombe, Thierry ^j   Duarte, Esther ^k   Geurts, Alexander C H ^l   Gracies, Jean Michel ^m   Haboubi, Naseer H J ⁿ   Juan, Francisco J ^o   Kasch, Helge ^p   Kätterer, Christian ^q   Kirazli, Yeşim ^r   Manganotti, Paolo ^s   Parman, Yeşim ^t   Paternostro Sluga, Tatjana ^u   Petropoulou, Konstantina ^v   Prempeh, Robert ^w   Rousseaux, Marc ^x   Slawek, Jaroslaw ^y   Tieranta, Niko ^z   more..

^a Kliniken Beelitz GmbH   (Germany)

^b HAYWOOD HOSPITAL   (United Kingdom)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g Landsklinikum Wiener Neustadt und Hochegg   (Austria)

^h Department of Neurological Science   (Italy)

ⁱ UNIVERSITY OF FERRARA   (Italy)

^j UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^k Del Mar University   (Spain)

^l SINT MAARTENSKLINIEK   (Netherlands)

^m HENRI MONDOR HOSPITAL   (France)

ⁿ NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^o UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^p AARHUS UNIVERSITY HOSPITAL   (Denmark)

^q Clinic for Neurorehabilitation and Paraplegiology   (Switzerland)

^r EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^s UNIVERSITY OF VERONA   (Italy)

^t ISTANBUL UNIVERSITY   (Turkey)

^u MEDICAL UNIVERSITY OF VIENNA   (Austria)

^v National Rehabilitation Center   (Greece)

^w Stirling Royal Infirmary   (United Kingdom)

^x LILLE UNIVERSITY HOSPITAL   (France)

^y MEDICAL UNIVERSITY OF GDANSK   (Poland)

^z Lapland Rehabilitation Centre   (Finland)

more..

Author keywords

Acquired brain injury; Adult spasticity; Botulinum toxin; Upper motor neurone syndrome

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; PHENOL; PLACEBO; STEROID;

ARTICLE; ASPIRATION PNEUMONIA; BRAIN INJURY; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COOPERATION; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSTONIA; EUROPE; FOLLOW UP; HUMAN; HYPERHIDROSIS; INFORMATION RETRIEVAL; INTERDISCIPLINARY COMMUNICATION; LONG TERM CARE; MEDICAL SPECIALIST; MUSCLE WEAKNESS; OCCUPATIONAL THERAPY; OFF LABEL DRUG USE; PHYSIOTHERAPY; PRACTICE GUIDELINE; PULMONARY ASPIRATION; REIMBURSEMENT; REPEATED DRUG DOSE; SHOULDER PAIN; SINGLE DRUG DOSE; SPASTICITY; UNSPECIFIED SIDE EFFECT;

EID: 59649116458     PISSN: 16501977     EISSN: None     Source Type: Journal    
DOI: 10.2340/16501977-0303     Document Type: Article

References (81)

1. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Florida: Year Book Medical Publishers; 1980, p. 485-494.
2. Gracies J-M. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle & Nerve 2005; 31: 535-551.
3. Gracies J-M. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle & Nerve 2005; 31: 552-571.
4. Ward AB, Aguilar M, De Beyl Z, Gedin S, Kanovsky P, Molteni F, et al. Use of botulinum toxin type A in management of adult spasticity - a European consensus statement. J Rehab Med 2003; 35: 1-2.
5. Jensen MD, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life. Neurology 2007; 68: 1178-1182.
6. Sommerfeld DK, Eek, EU-B, Svensson A-K, Holmqvist LW, von Arbin MH. Spasticity after stroke. Its occurrence and association with motor impairments and activity limitations. Stroke 2004; 35: 134-139.
7. Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehab 2002; 16: 515-522.
8. Leathly MJ, Gregson JM, Moore AP, Smith TL, Sharma AK, Watkins CL. Predicting spasticity after stroke in those surviving 12 months. Clin Rehab 2004; 18: 438-443.
9. Van Kuijk AA, Hendriks HT, Pasman JW, Kremer BH, Geurts AC. Are clinical characteristics associated with upper-extremity hypertonia in severe ischaemic supratentorial stroke? J Rehabil Med 2007; 39: 33-37.
10. Al Buhairi AR, Phillips SJ, Llewellyn G, Jan MM. Prediction of infarct topography using the Oxfordshire Community Stroke Project classification of stroke subtypes. J Stroke Cerebrovasc Dis 1998; 7: 339-343.
11. Duncan PW, Zorowitz R, Bates B, Choi JY, Glasberg JJ, Graham GD, et al. Management of adult stroke rehabilitation care. Stroke 2005; 36: e100-e143.
12. Turner-Stokes L, Ward A. Botulinum toxin in the management of spasticity in adults. Clin Med 2002; 2: 128-130.
13. Royal College of Physicians. Guidance to good practice. Guidelines for the use of botulinum toxin (BTX) in the management of spasticity in adults. London: Royal College of Physicians; 2002.
14. van Kuijk AA, Geurts AC, Bevaart BJ, van Linbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. J Rehabil Med 2002; 34: 51-61.
15. Wallesch C-W, Maes E, Lecomte P, Bartels C. Cost-effectiveness of botulinum toxin type A injection patients with spasticity following a stroke: a German perspective. Eur J Neurol 1997; 4 Suppl 2: S53-S57.
16. Radensky PW, Archer JW, Dournaux SF, O'Brien CF. The estimated cost of managing focal spasticity: a physician practice patterns survey. Neurorehab Neural Repair 2001; 15: 57-68.
17. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type A in the treatment of post-stroke spasticity. J Rehabil Med 2005; 37: 252-257.
18. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006; 13 Suppl 4: 10-19.
19. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004; 20: 981-990.
20. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006; 13 Suppl 4: 35-40.
21. De Almeida AT, De Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 2007; 9 Suppl 1: 17-22.
22. Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007; 29: 1325-1337.
23. Amirali A, Mu L, Gracies JM, Simpson DM. Anatomical localization of motor endplate bands in the human biceps brachii. J Clin Neuromuscul Dis 2007; 9: 306-312.
24. Gracies J-M, Weisz DJ, Yang BY, Flanagan S, Simpson D. Impact of botulinum toxin type A (BTX-A) dilution and endplate targeting technique in upper limb spasticity. Ann Neurol 2002; 52 Suppl 1: S87.
25. Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology 2002; 58: 805-807.
26. Chin T, Selber P, Graham HK. Accuracy of intramuscular injection of botulinum toxin A: a comparison between manual needle placement and placement by guided electrical stimulation. Dev Med Child Neurol 2003; 45 Suppl: 9.
27. Berweck S, Schroeder AS, Fietzek UM, Heinen F. Sonography-guided injection of botulinum toxin in children with cerebral palsy. Lancet 2004; 363: 249-250.
28. Berweck S, Wissel J. Sonographic imaging for guiding botulinum toxin injections in limb muscles. Adv Clin Neurosci Rehab 2004; 4: 28-31.
29. Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, et al. for the BOTOX Poststroke Spasticity Group. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004; 63: 1971-1973.
30. Greene P, Fahn S. Development of antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: DasGupta BR, editor. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press; 1993, p. 651-654.
31. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9: 213-217.
32. Zuber M, Sebald M, Bathien N, Derecondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type-A botulinum toxin - frequency and significance. Neurology 1993; 43: 1715-1718.
33. Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, et al. Formulation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: pooled-data analysis of three clinical trials. Clin Ther 2007; 29: 683-690.
34. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Letts 1995; 201: 37-40.
35. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehab 1998; 12: 381-388.
36. Frasson E, Priori A, Ruzzante B, Didonè G, Bertolasi L. Nerve stimulation boosts botulinum toxin action in spasticity. Mov Disord 2005; 20: 624-629.
37. Chen R, Karp BI, Golstein SR, Bara-Jimenez W, Yaseen Z, Hallet M. Effect of muscle activity immediately after botulinum toxin injection for writer's cramp. Mov Disord 1999; 14: 307-312.
38. Carda S, Molteni F. Taping versus electrical stimulation after botulinum toxin type A injection for wrist and finger spasticity. A case-control study. Clin Rehab 2005; 19: 621-626.
39. Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehab 2007; 21: 331-337.
40. Nudo RJ, Wise BM, SiFuentes F, Milliken GW. Neural substrates for the effects of rehabilitation training on motor recovery after ischemic infarct. Science 1996; 272: 1791-1794.
41. Ward AB, Begg A, Kent R, Landham L, Luttrell S, Robertson A, et al, editors. Community management and referral of spasticity following stroke. Herts: Connectmedical, Medendium Group Publishing Ltd; 2004.
42. Bakheit AMO, Fedorova NV, Skoromets AA, Timberbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated cycles. J Neurol Neurosurg Psychiatry 2004; 75: 1558-1561.
43. Bakheit AMO, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of botulinum toxin upper limb spasticity in patients with stroke. Eur J Neurol 2001; 8: 559-565.
44. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double-blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000; 69: 217-221.
45. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, DO M, et al. for the BOTOX Post-stroke spasticity group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347: 395-400.
46. Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix. X, Joseph PA, et al. A randomised double-blind placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996; 61: 265-269.
47. Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper limb spasticity after a stroke. Arch Phys Med Rehab 2004; 85: 1063-1069.
48. Cardoso E, Rodriguez B, Lucena R, Reis de Olivera I, Pedreira G, Melo A. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke. Arq Neuropsiquiatr 2005: 63: 3-33.
49. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45: 712-717.
50. Francis HP, Wade DT, Turner-Stokes L, Kingswell RS, Dott CS, Coxon EA. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry 2004; 75: 1547-1551.
51. Hyman N, Barnes M, Bhakta B, Cozens, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry, 2000; 68: 707-712.
52. Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinum toxin type A in the treatment of spastic foot after stroke. Am J Phys Med Rehab 1998; 77: 510-515.
53. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005; 26: 26-31.
54. Marco E, Duarte E, Vila J, Tejero M, Guillen A, Boza R, et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J Rehab Med 2007; 39: 440-447.
55. Pitttock SJ, Moore AP, Hardiman O, Ehler E, Kovac M, Bojakowski J, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003; 15: 289-300.
56. Richardson D, Sheean G, Werring D, Desai M, Edwards S, Greenwood R, Thompson A. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000; 69: 499-506.
57. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. Botulinum toxin type A in the treatment of upper limb spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306-1310.
58. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehab 2000; 14: 5-13.
59. Snow BJ, Tsui JKC, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28: 512-515.
60. Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005; 27: 176-184.
61. Verplancke D, Snape S, Salisbury CF, Jones PW, Ward AB. A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury. Clin Rehab 2005; 19: 117-125.
62. Stoquart GG, Detrembleur C, Palumbo S, Deltombe T, Lejeune TM. Effect of Botulinum toxin injection in rectus femoris on stiff-knee gait in stroke patients: a prospective observational study. Arch Phys Med Rehabil 2008; 89: 56-61.
63. Caty GD, Detrembleur C, Bleyenheuft C, Deltombe T, Lejeune TM. Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation and quality of life among stroke patients presenting with a stiff-knee gait. Stroke 2008; 39: 2803-2808.
64. Yelnik AP, Cole FM, Bonan IV, Vicaut E. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A. J Neurol Neurosurg Psychiatry 2007; 78: 845-848.
65. Lim J-Y, Koh J-H, Paik N-J. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain. Stroke 2008; 39: 126-131.
66. Medical Research Council of the UK. Aids to the investigation of peripheral nerve injuries. Memorandum No 45. London: Pendragon House; 1976, p. 6-7.
67. Bohannon RW, Smith MB. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206-207.
68. Mahoney FI, Barthel DW. Maryland State Medical Journal 1965; 14: 56-61.
69. Ashford S, Turner-Stokes L. Goal attainment for spasticity management using botulinum toxin. Physiother Res Int 2006; 11: 24-34.
70. Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle & Nerve 1997; Suppl 6: S208-S220.
71. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006; 13 Suppl 4: 1-9.
72. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 592-596.
73. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004; 19 Suppl 8: S129-S136.
74. Foster KA, Bigalke H, Aoki KR. Botulinum neurotoxin - from laboratory to bedside. Neurotox Res 2006; 9: 133-140.
75. Wilkinson GR. In Hardman JG, Limbard LE, Goodman A, editors. The pharmacological basis of therapeutics. 10th edn. New York, NY: McGraw Hill; 2001, p. 3-30.
76. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005; 20: 592-597.
77. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injection affects muscle paralysis. Muscle Nerve 1993; 16: 964-969.
78. Childers MK, Kornegay JN, Aoki R, Otaviani L, Bogan DJ, Petroski G. Evaluating end-plate-targeted injections of botulinum toxin type A in a canine model. Muscle Nerve 1998; 21: 653-655.
79. Lagalla G, Danni M, Reiter F, Ceravolo MG, Provinciali L. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehab 2000; 79: 377-384.
80. Bakheit AMO, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31: 2401-2406.
81. Young RR. Spasticity: a review. Neurology 1994; 44 Suppl 9; S12-S20.